Senti Biosciences (NASDAQ:SNTI) Receives “Buy” Rating from Chardan Capital

Senti Biosciences (NASDAQ:SNTI)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 40.06% from the stock’s previous close.

Senti Biosciences Trading Down 28.6 %

Shares of SNTI opened at $7.14 on Monday. The stock has a market capitalization of $32.77 million, a PE ratio of -0.46 and a beta of 2.69. The firm’s 50 day moving average is $2.46 and its 200-day moving average is $2.66. Senti Biosciences has a 12 month low of $1.52 and a 12 month high of $16.94.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.